Novel Therapeutic Targets in Non-small Cell Lung Cancer

被引:117
|
作者
Janku, Filip [1 ,2 ]
Garrido-Laguna, Ignacio
Petruzelka, Lubos B. [2 ]
Stewart, David J. [3 ]
Kurzrock, Razelle
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Unit 455, Houston, TX 77030 USA
[2] Charles Univ Prague, Dept Oncol, Fac Med 1, CR-11636 Prague 1, Czech Republic
[3] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
Non-small cell lung cancer; Molecular target; Mutation; EGFR; VEGF; VEGFR; KRAS; BRAF; PIK3CA; EML4-ALK; IGF-1R; GROWTH-FACTOR-RECEPTOR; PHASE-III TRIAL; IN-SITU HYBRIDIZATION; GENE COPY NUMBER; EML4-ALK FUSION GENE; HER2 KINASE DOMAIN; SOMATIC MUTATIONS; ACQUIRED-RESISTANCE; 1ST-LINE GEFITINIB; MOLECULAR PREDICTORS;
D O I
10.1097/JTO.0b013e31822944b3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of personalized medicine with a focus on novel targeted therapies has supplanted the one-size-fits-all approach to the treatment of many cancers, including non-small cell lung cancer. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abrogate cell signaling that perpetuates cancer progression. Critical targets activating procancer pathways include, but are not limited to, epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (MET), vascular endothelial growth factor (VEGF), VEGF receptor, GTPase KRAS (KRAS), receptor tyrosine protein kinase erbB-2 (HER2), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4ALK), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), serine/threonine-protein kinase B-raf (BRAF), and insulin-like growth factor 1 receptor (IGF1R). Some target-directed therapies, such as epidermal growth factor receptor tyrosine kinase inhibitors and anti-VEGF monoclonal antibody, have already been approved for clinical use. Others, such as those targeted to MET, VEGFR, HER2, PIK3CA, and IGF-1R, are in clinical testing. This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy.
引用
收藏
页码:1601 / 1612
页数:12
相关论文
共 50 条
  • [1] Novel therapeutic targets in non-small cell lung cancer
    Alamgeer, Muhammad
    Ganju, Vinod
    Watkins, D. Neil
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) : 394 - 401
  • [2] Molecular therapeutic targets in non-small cell lung cancer
    Sankar, Kamya
    Gadgeel, Shirish M.
    Qin, Angel
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (08) : 647 - 661
  • [3] Novel Targets in Advanced Non-Small Cell Lung Cancer
    Liu, Stephen, V
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07) : 426 - 429
  • [4] NOVEL TARGETS AND THERAPIES IN NON-SMALL CELL LUNG CANCER
    Janne, Pasi A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S93 - S93
  • [5] Identification of New Therapeutic Targets in Non-Small Cell Lung Cancer
    O'Donnell, K. A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : S4 - S4
  • [6] Lymphatic metastasis in non-small cell lung cancer: recent discoveries and novel therapeutic targets
    Diao, Xiayao
    Guo, Chao
    Li, Shanqing
    [J]. CANCER COMMUNICATIONS, 2022, 42 (12) : 1403 - 1406
  • [7] Identification and validation of novel prognostic biomarkers and therapeutic targets for non-small cell lung cancer
    Lai, Li-Ting
    Ren, Yuan-Hui
    Huai, Ya-Jun
    Liu, Yu
    Liu, Ying
    Wang, Shan-Shan
    Mei, Jin-Hong
    [J]. FRONTIERS IN GENETICS, 2023, 14
  • [8] Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
    Rebuzzi, Sara Elena
    Zullo, Lodovica
    Rossi, Giovanni
    Grassi, Massimiliano
    Murianni, Veronica
    Tagliamento, Marco
    Prelaj, Arsela
    Coco, Simona
    Longo, Luca
    Dal Bello, Maria Giovanna
    Alama, Angela
    Dellepiane, Chiara
    Bennicelli, Elisa
    Malapelle, Umberto
    Genova, Carlo
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 25
  • [9] Bonafide Targets of Deregulated microRNAs in Non-Small Cell Lung Cancer as Tool to Identify Novel Therapeutic Targets: A Review
    Cipollini, Monica
    Landi, Stefano
    Gemignani, Federica
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (01) : 55 - 72
  • [10] Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
    de Jong, Dorine
    Das, Jeeban P.
    Ma, Hong
    Pailey Valiplackal, Jacienta
    Prendergast, Conor
    Roa, Tina
    Braumuller, Brian
    Deng, Aileen
    Dercle, Laurent
    Yeh, Randy
    Salvatore, Mary M.
    Capaccione, Kathleen M.
    [J]. CANCERS, 2023, 15 (10)